Abstract
Arthritis, a systemic autoimmune disease that involves synovial growth and cartilage breakdown produces persistent inflammation of connective tissue, particularly in the joints. Arthritis is more common in persons over 65, but it can strike anyone at any age (including children). Antiarthritic medicines can help with arthritis treatment, but they can also cause dizziness, drowsiness, headaches, swollen or painful gums, hair loss, decreased appetite, mouth sores, rash, diarrhoea and several adverse side effects. Thus, there is a need for the development of novel antiarthritic drugs. Therefore, the present study focuses on the green synthesis of silver nanoparticles using leaf extracts of Laurus nobilis L. and evaluating its antiarthritic activity. The silver nanoparticles were synthesized and characterized using UV-Vis spectroscopy and dynamic light scattering. The in vitro antiarthritic activity of the green synthesized AgNPs was determined using protein denaturation and RBC membrane stabilization methods. The UV-Vis spectrum showed the nanoparticle peak at 396 nm, and the average size of the nanoparticle was found to be 78.1 nm. Five concentrations (50 mu g, 100 mu g, 250 mu g, 500 mu g and 1000 mu g) of AgNPs were used to compare with the standard drug (aspirin). AgNPs showed a significant inhibition percentage compared with the standard drug. An increase in concentration increases the inhibition percentage. Maximum inhibition of protein denaturation and membrane stabilization of AgNPs was observed to be 53.47 +/- 0.33% and 62.43 +/- 0.25% at 1000 mu g concentration. Therefore, AgNPs synthesized from L. nobilis can be used for the development of novel antiarthritic drugs.